Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits
Pharmaceutical Research · 2024
DOI: 10.1007/s11095-024-03721-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Steven A Giannos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA. stevena.giannos@viatris.com. Hauptthemen laut MEDLINE: Ranibizumab, Bevacizumab, Ophthalmic Solutions, Retina. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United Molecule, LLC, Carl Marshall and Mildred Almen Reeves Foundation.
Abstract (Originalsprache)
Purpose
Wet age-related macular degeneration (AMD) is a blinding retinal disease. Monthly intravitreal anti-VEGF antibody injections of bevacizumab (off-label) and ranibizumab (FDA approved) are the standard of care. Antibody aggregation may interfere with ocular absorption/distribution. This study assessed topical delivery of dilute antibodies to the posterior segment of rabbit eyes using a novel anti-aggregation formula (AAF).
Methods
Bevacizumab, or biosimilar ranibizumab was diluted to 5 mg/ml in AAF. All rabbits were dosed twice daily. Substudy 1 rabbits (bevacizumab, 100 µl eye drops): Group 1 (bevacizumab/AAF, n = 6); Group 2 (bevacizumab/PBS, n = 7) and Vehicle control (AAF, n = 1). Substudy 2 rabbits (ranibizumab biosimilar/AAF, 50 µl eye drops): (ranibizumab biosimilar/AAF, n = 8). At 14.5 days, serum was drawn from rabbits. Aqueous, vitreous and retina samples were recovered from eyes and placed into AAF aliquots. Tissue analyzed using AAF as diluent.
Results
Bevacizumab in AAF permeated/accumulated in rabbit aqueous, vitreous and retina 10 times more, than when diluted in PBS. AAF/0.1% hyaluronic acid eye drops, dosed twice daily, provided mean tissue concentrations (ng/g) in retina (29.50), aqueous (12.34), vitreous (3.46), and serum (0.28 ng/ml). Additionally, the highest concentration (ng/g) of ranibizumab biosimilar was present in the retina (18.0), followed by aqueous (7.82) and vitreous (1.47). Serum concentration was negligible (< 0.04 ng/ml). No irritation was observed throughout the studies.
Conclusions
Bevacizumab and ranibizumab, in an AAF diluent eye drop, can be delivered to the retina, by the twice daily dosing of a low concentration mAb formulation. This may prove to be an adjunct to intravitreal injections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA. stevena.giannos@viatris.com.
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA.
- Department of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX, USA. prgupta@utmb.edu.
Förderung
- United Molecule, LLC
- Carl Marshall and Mildred Almen Reeves Foundation
Zitieren
APA
Giannos, S. A., Kraft, E. R., Luisi, J. D., Schmitz-Brown, M. E., Reffatto, V., Merkley, K. H., & Gupta, P. K. (2024). Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03721-2
Vancouver
Giannos SA, Kraft ER, Luisi JD, Schmitz-Brown ME, Reffatto V, Merkley KH, et al. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03721-2
BibTeX
@article{Giannos2024,
author = {Giannos, Steven A and Kraft, Edward R and Luisi, Jonathan D and Schmitz-Brown, Mary E and Reffatto, Valentina and Merkley, Kevin H and Gupta, Praveena K},
title = {Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits},
journal = {Pharmaceutical Research},
year = {2024},
doi = {10.1007/s11095-024-03721-2}
}
EUVIMED